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Purpose/Objective: In line with the implementation of new treatment 
methods like IMRT and RapidArc, where the margins are reduced and 
the treatment plans demand high accuracy in the daily treatment we 
felt obliged to have a closer look at our strategy for verification of the 
treatment field. Even though we already have used IGRT for prostate 
cancer patients since 2005, which was extended in 2009 to include 
patients with brain tumours, we decided to extend our IGRT strategy 
further to all patient groups. In our clinic we have 11 accelerators and 
treat about 260 patients daily. 
Materials and Methods: In the autumn of 2010, we had our first 
meeting in an interdisciplinary group consisting of physicists, 
physicians and RTTs (nurses). The purpose of the group was to make 
an IGRT strategy for all patient groups. One of our challenges was our 
accelerators, which were of different models, resulting in 4 different 
verification systems - portal image, on board image (OBI), cone beam 
CT and Exactrac. The task of the group was to define which 
verification systems was best for which diagnosis, define margins for 
set-up uncertainties, whether to use bone or soft-tissue match, make 
plans for a physician/physicist control of the match and to educate 
the staff. 
Results: In 2012, approximately 95 % of the treatments are image 
guided which is equivalent to 55.000 image guided treatments per 
year. To make the transition as smooth as possible, it was necessary 
to make a gradual transition. We started out testing the new strategy 
on 3 accelerators for 4 months, and all physicists, physicians and RTTs 
had a 2 hour theoretical lesson in the changes in their part of the 
treatment preparation and therapy. After that, the staff had hands-on 
lessons for a couple of hours. During the first 4 months, the 
interdisciplinary group met to make small adjustments. As of 
September 1. 2011 IGRT is a daily routine in our clinic.  
Conclusions: The transition has not been as difficult as we could have 
feared. All members of the staff have worked together to make it 
happen. The RTTs say that it makes them feel more comfortable to 
give a high precision treatment now that they check every day that 
the positioning of the patient is correct. Reports of unintended events 
linked to IGRT has drop from 10 to fewer than 3 a year. The process of 
adjusting the IGRT strategy to changes in the clinic, new treatment 
methods and strategies is on-going.  
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Purpose/Objective: The purpose of this study was to systematically 
analyse and evaluate the effectiveness of interstitial brachytherapy on 
periocular squamous cell carcinoma (POSCC) in horses in decreasing 
tumour recurrence rates. A further evaluation of treatment technique 
will define appropriateness of wire placement in relation to dose 
distribution parameters. 
Materials and Methods: The study included records of 104 horses with 
histologically or clinically confirmed periocular squamous cell 
carcinoma (POSCC). The patients were treated in a rural Australian 
clinic between 1999 and 2007 with permanent Gold (Au198) wire 
manually implanted without the use of radiation therapy specific 
planning software, dosimetry or expertise. Recurrence was defined as 
the post-irradiation regrowth of SCC at the same site of treatment. 
Follow-up information was obtained for 44 of the 104 cases. 
Treatment applications for each individual case (104) were modelled 
and replicated and dose distributions calculated through the use of 
Varian BrachyVisionTM Treatment Planning Software.  
Results: Recurrence was noted in 30 of the 44 cases where follow-up 
was evident (as reported via owner or veterinarian). The treated 
lesions were reported to have resolved in 14 of the 44 cases, however, 
follow-up information was not available for 60/104 cases.  
Conclusions: The results of this study question the efficacy of 
brachytherapy treatment applications without appropriate radiation 
therapy planning, dosimetry and expertise. The results further support 
the need for protocol based treatment implementation within 
veterinary oncology to mirror current applications in human 
treatments and with a view to enhancing treatment outcomes with 
reference to recurrence rates. 
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Purpose/Objective: To report the tolerability of breast IORT using a 
single channel balloon catheter applicator.  
Materials and Methods: From February 2011 to November 2012, we 
treated 60 patients aged 36 to 85 (median 63) years by intraoperative 
HDR-afterloading therapy intended as a tumour bed boost. According 
to ASTRO suitability criteria, 19 of them would have qualified for 
partial breast irradiation (PBI)only, 24 would have been considered 
cautionary. Patients were eligible for the method with cT1 (n=49) or 
small cT2 (n=11) tumours, no multicentricity, and a skin-tumour-
distance of > 1.5 cm. Irradiation was performed using balloon catheter 
applicators with volumes of 35(n=50), 40(n=9) or 50 ml (n=1), resulting 
in 1 cm depth tissue doses of 8.9, 9.1 and 9.5 Gy, respectively. The 
intended dose of 20 Gy to the applicator surface was given in 51 
patients. In 9 patients, irradiation was terminated early due to an 
excess in online-measured skin dose (limit set at 8 Gy). Breast 
volumes ranged from 317 to 3893 (median:1037) ml. According to 
ASTRO quality criteria for PBI, not more than 60% of breast volume 
should receive more than 50% of the prescribed dose in 1 cm tissue 
depth. This was fulfilled in all but two patients with breast volumes of 
317 and 423 ml. Percutaneous whole breast irradiation (WBI) (50.4 Gy, 
3D-conformal) in patients not receiving postoperative chemotherapy 
(n=38) was started 33 to 63 (median 42) days after IORT. In 22 cases, 
final histology revealed indications for chemotherapy. Whole breast 
irradiation(WBI) was performed thereafter, starting 138 to 238 
(median: 171) days after IORT. 
Results: Prolongation of anaesthesia due to irradiation time and 
transport was 40 minutes in mean. Measured skin dose ranged from 
1.381 to 8.2 (median: 5.6) Gy. Acute side effect was a mild or 
moderate erythema in20% of patients decreasing till the start of WBI 
and then aggravating again. Edema was seen in 40% of patients some 
days after IORT, resolving till start of WBI, appearing again as a side 
effect of EBRT and decreasing again in the year after RT. Induration of 
the tumour bed started some days after IORT, resolved inpatients 
receiving postoperative chemotherapy before WBI, but was seen as a 
side effect of EBRT, slowly resolving during follow-up. Skin 
desquamation was seen only as a side effect of WBI. Patients receiving 
chemotherapy showed rather less side effects of WBI due to the 
prolonged time between IORT and EBRT. 
Conclusions: The side effects observed after intraoperative HDR-
balloon catheter afterloading plus WBI did not differ neither in quality 
nor strength from what we see in WBI plus percutaneous tumour bed 
boost. Thus, we consider the method to be a safe alternative to 
percutaneous boost and prefer it for boosting small breast cancers, as 
with the IORT application we are certain to reduce geographic miss of 
the tumour bed. 
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Purpose/Objective: Rectal volume change is a proved source of 
variation during external beam radiotherapy. Vaginal cuff 
brachytherapy is one of the most widely and settle brachytherapy 
procedures wordwile. Some groups advocate a previous rectum 
cleansing, despite this fact no studies exist analysing the 
consequences of rectal distention during vaginal cuff brachytherapy. 
The aim of our study was to define how rectal distention affects 
dosimetric values on organs at risk. 
Materials and Methods: CT sets (337) derived from 92 patients 
treated with vaginal cuff brachytherapy were re-segmented and re-
planned for study purpose under the same parameters. Rectum DVH 
